Search Results - "Finazzi, G."

How to manage essential thrombocythemia by Finazzi, G

“…I use the hematological, morphological and molecular criteria recently established by the World Health Organization to diagnose essential thrombocytemia. In…”
Get full text

The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances by Barbui, T, Thiele, J, Gisslinger, H, Finazzi, G, Vannucchi, A.M, Tefferi, Ayalew

“…Abstract Clinical evidence supports the need of changing the diagnostic criteria of the 2008 updated WHO classification for polycythemia vera (PV), essential…”
Get full text

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study by Tefferi, A, Rumi, E, Finazzi, G, Gisslinger, H, Vannucchi, A M, Rodeghiero, F, Randi, M L, Vaidya, R, Cazzola, M, Rambaldi, A, Gisslinger, B, Pieri, L, Ruggeri, M, Bertozzi, I, Sulai, N H, Casetti, I, Carobbio, A, Jeryczynski, G, Larson, D R, Müllauer, L, Pardanani, A, Thiele, J, Passamonti, F, Barbui, T

“…Under the auspices of an International Working Group, seven centers submitted diagnostic and follow-up information on 1545 patients with World Health…”
Get full text

Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders by Finazzi, G

“…Primary antithrombotic prevention with aspirin is not indicated in asymptomatic patients with confirmed antiphospholipid (aPL) positivity without systemic…”
Get full text

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia by Finazzi, G, Barbui, T

“…Major causes of morbidity and mortality in polycythemia vera (PV) and essential thrombocythemia (ET) are represented by thrombosis and bleeding, progression to…”
Get full text

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) by Finazzi, G, Marchioli, R, Brancaccio, V, Schinco, P, Wisloff, F, Musial, J, Baudo, F, Berrettini, M, Testa, S, D'Angelo, A, Tognoni, G, Barbui, T

“…The optimal intensity of oral anticoagulation for the prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome is uncertain…”
Get full text

Improvement of light to biomass conversion by de-regulation of light-harvesting protein translation in Chlamydomonas reinhardtii by Beckmann, J., Lehr, F., Finazzi, G., Hankamer, B., Posten, C., Wobbe, L., Kruse, O.

“…The efficient use of microalgae to convert sun light energy into biomass is limited by losses during high light illumination of dense cell cultures in closed…”
Get full text

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia by Barbui, T, Vannucchi, A M, Buxhofer-Ausch, V, De Stefano, V, Betti, S, Rambaldi, A, Rumi, E, Ruggeri, M, Rodeghiero, F, Randi, M L, Bertozzi, I, Gisslinger, H, Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Falcone, C, Tefferi, A

Get full text

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study by Finazzi, Guido, Caruso, Vanesa, Marchioli, Roberto, Capnist, Giovanni, Chisesi, Teodoro, Finelli, Carlo, Gugliotta, Luigi, Landolfi, Raffaele, Kutti, Jack, Gisslinger, Heinz, Marilus, Raphael, Patrono, Carlo, Pogliani, Enrico Maria, Randi, Maria Luigia, Villegas, Ana, Tognoni, Gianni, Barbui, Tiziano

“…Progression to acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) is a possible evolution of polycythemia vera (PV), but whether some patients are at…”
Get full text

Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations by Zaja, F., Carpenedo, M., Baratè, C., Borchiellini, A., Chiurazzi, F., Finazzi, G., Lucchesi, A., Palandri, F., Ricco, A., Santoro, C., Scalzulli, P.R.

“…Thrombopoietin receptor agonists (TPO-RAs) are currently indicated for continuous treatment of chronic primary immune thrombocytopenia (ITP). However, there is…”
Get full text

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists by De Stefano, V, Ruggeri, M, Cervantes, F, Alvarez-Larrán, A, Iurlo, A, Randi, M L, Elli, E, Finazzi, M C, Finazzi, G, Zetterberg, E, Vianelli, N, Gaidano, G, Rossi, E, Betti, S, Nichele, I, Cattaneo, D, Palova, M, Ellis, M H, Cacciola, R, Tieghi, A, Hernandez-Boluda, J C, Pungolino, E, Specchia, G, Rapezzi, D, Forcina, A, Musolino, C, Carobbio, A, Griesshammer, M, Sant’Antonio, E, Vannucchi, A M, Barbui, T

“…The optimal duration of treatment with vitamin K antagonists (VKA) after venous thromboembolism (VTE) in patients with Philadelphia-negative myeloproliferative…”
Get full text

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria by Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Rumi, E, Ruggeri, M, Rodeghiero, F, Randi, M L, Bertozzi, I, Vannucchi, A M, Antonioli, E, Gisslinger, H, Buxhofer-Ausch, V, Gangat, N, Rambaldi, A, Tefferi, A, Barbui, T

“…In an international study of 1104 patients with essential thrombocythemia (ET), a histological review according to the 2008 World Health Organization (WHO)…”
Get full text

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients by De Stefano, V, Vannucchi, A M, Ruggeri, M, Cervantes, F, Alvarez-Larrán, A, Iurlo, A, Randi, M L, Pieri, L, Rossi, E, Guglielmelli, P, Betti, S, Elli, E, Finazzi, M C, Finazzi, G, Zetterberg, E, Vianelli, N, Gaidano, G, Nichele, I, Cattaneo, D, Palova, M, Ellis, M H, Cacciola, E, Tieghi, A, Hernandez-Boluda, J C, Pungolino, E, Specchia, G, Rapezzi, D, Forcina, A, Musolino, C, Carobbio, A, Griesshammer, M, Barbui, T

“…We retrospectively studied 181 patients with polycythaemia vera ( n =67), essential thrombocythaemia ( n =67) or primary myelofibrosis ( n =47), who presented…”
Get full text

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis by Barbui, T, Carobbio, A, Finazzi, G, Guglielmelli, P, Salmoiraghi, S, Rosti, V, Rambaldi, A, Vannucchi, A M, Barosi, G

Get full text

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 by BARBUI, Tiziano, CAROBBIO, Alessandra, OTTOMANO, Cosimo, MARCHIOLI, Roberto, CUCCOVILLO, Ivan, BOTTAZZI, Barbara, MANTOVANI, Alberto, RAMBAIDI, Alessandro, FINAZZI, Guido, VANNUCCHI, Alessandro M, BAROSI, Giovanni, ANTONIOLI, Elisabetta, GUGLIELMELLI, Paola, PANCRAZZI, Alessandro, SALMOIRAGHI, Silvia, ZILIO, Pio

“…We tested the hypothesis that levels of pentraxin high sensitivity C-reactive protein and pentraxin 3 might be correlated with cardiovascular complications in…”
Get full text

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis by Finazzi, M C, Carobbio, A, Cervantes, F, Isola, I M, Vannucchi, A M, Guglielmelli, P, Rambaldi, A, Finazzi, G, Barosi, G, Barbui, T

Get full text

central role of the green alga Chlamydomonas reinhardtii in revealing the mechanism of state transitions by Finazzi, Giovanni

“…This review focuses on the essential role played by the green alga Chlamydomonas reinhardtii in revealing both the mechanism and the physiological consequences…”
Get full text

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) by Barosi, G, Tefferi, A, Besses, C, Birgegard, G, Cervantes, F, Finazzi, G, Gisslinger, H, Griesshammer, M, Harrison, C, Hehlmann, R, Hermouet, S, Kiladjian, J-J, Kröger, N, Mesa, R, Mc Mullin, M F, Pardanani, A, Passamonti, F, Samuelsson, J, Vannucchi, A M, Reiter, A, Silver, R T, Verstovsek, S, Tognoni, G, Barbui, T

“…The discovery of somatic mutations, primarily JAK2 V617F and CALR , in classic BCR-ABL1 -negative myeloproliferative neoplasms (MPNs) has generated interest in…”
Get full text

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results by PENGO, V., CRIPPA, L., FALANGA, A., FINAZZI, G., MARONGIU, F., MOIA, M., PALARETI, G., POLI, D., TESTA, S., TIRAFERRI, E., TOSETTO, A., TRIPODI, A., SIRAGUSA, S., MANOTTI, C.

“…In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the…”
Get full text

Quantitative risk assessment of verocytotoxin-producing Escherichia coli O157 and Campylobacter jejuni related to consumption of raw milk in a province in Northern Italy by Giacometti, F, Serraino, A, Bonilauri, P, Ostanello, F, Daminelli, P, Finazzi, G, Losio, M N, Marchetti, G, Liuzzo, G, Zanoni, R G, Rosmini, R

“…A quantitative risk assessment was developed to describe the risk of campylobacteriosis and hemolytic uremic syndrome (HUS) linked to consumption of raw milk…”
Get more information